Therefore, treatment with CD38 antibodies may exhibit anti-tumor activity by releasing T-cell suppression via inhibition of such immunosuppressive cells, and may have therapeutic potential for solid tumors beyond hematologic malignancies such as MM. This evidence concerns the gene CD38 and Miyoshi myopathy.